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Background: Genistein, one of the major isoﬂavones, has received great attention as a 
  phytoestrogen and potential cancer chemoprevention agent. However, the dissolution and bio-
availability of genistein from solid oral preparations is low due to its poor water solubility.
Methods: In order to improve the oral bioavailability of genistein, genistein nanoparticles were 
prepared by the nanoprecipitation technique using Eudragit® E100 as carriers and an optimized 
formulation of mass ratio (genistein:Eudragit E100, 1:10). The mean particle size of genistein 
nanoparticles was approximately 120 nm when diluted 100 times with distilled water. The drug-
loaded nanoparticles were spherical on observation by transmission electric microscopy.
Results: Encapsulation efficiency and drug loading of the genistein nanoparticles were approxi-
mately 50.61% and 5.02%, respectively. Release of drug from the genistein nanoparticles was 
two times greater than that from the conventional capsules. After administration of genistein 
suspension or genistein nanoparticles at a single dose of 100 mg/kg to fasted rats, the relative 
bioavailability of genistein from the nanoparticles compared with the reference suspension 
was 241.8%.
Conclusion: These results suggested that a nanoparticle system is a potentially promising 
formulation for the efficient delivery of poorly water-soluble drugs by oral administration.
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Introduction
Genistein (5, 7, 4′-triatomic isoﬂavone, see Figure 1) is a primary active component 
of the soybean, kudzuvine root, scoparius, and other leguminous plants. As one of the 
most extensively studied isoﬂavones, it is generally recognized as a phytoestrogen.1 With 
its weak estrogenic and antiestrogenic properties, genistein is not only used as an anti-
oxidant, ie, an inhibitor of protein tyrosine kinase or topoisomerase II, but is also used 
to induce cell differentiation.2 Asiatic women with a high intake of isoﬂavones from 
soy products have been shown to have a decreased risk of osteoporosis,   cardiovascular 
disease, breast and uterine cancer, and climacteric syndrome.3,4 Although frequent 
reports demonstrate positive inﬂuences of isoﬂavones on human health, the clinical 
application of genistein is hindered by its disadvantages, including poor solubility in 
water and low serum levels after oral administration.5
Various drug delivery systems, including self-nanoemulsified systems, 
  superparamagnetic systems, and chitosan microspheres, have been used to increase the 
dissolution and bioavailability of genistein. It is reported that the optimized   formulation 
dissolved more than 90% of genistein over five minutes in a self-nanoemulsified 
drug delivery system.6 Genistein encapsulated in Fe3O4-carboxymethylated chitosan 
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nanoparticles shows greater water solubility than the free 
genistein.5
The Eudragit® E cationic copolymer has been widely used 
to improve the solubility of poorly water-soluble drugs.7 It 
has a basic site containing tertiary amine groups which are 
ionized in gastric ﬂuid.8 Therefore, Eudragit E is easy to 
dissolve in the gastric environment. Eudragit E is one type 
of high polymer material, and is nontoxic, easily absorbed 
orally, and is widely used in coating and film forming. In 
recent years, it has been used to prepare microcapsules and 
nanoformulations to improve the solubility of poorly water-
soluble drugs. It is reported that some new nanoparticle 
formulations of naringenin-Eudragit E nanoparticles and 
quercetin-Eudragit E nanoparticles have been prepared for 
improving solubility.9,10
In this study, a drug delivery system for genistein 
was designed based on Eudragit E nanoparticles. It was 
expected that this system would improve the water   solubility 
of the drug, and hence improve its bioavailability by 
oral   administration. This novel nanoparticle system was 
characterized by its particle size, morphology, encapsulation 
efficiency, drug loading, and dissolution. Furthermore, the 
oral bioavailability of genistein nanoparticles was assessed 
and compared with that of a genistein suspension.
Materials and methods
Materials
Genistein was purchased from Shanxi Huike   Botanical 
Development Co Ltd (Xi’an, Shanxi, China). Standard 
phenacetin was supplied by the National Institute for 
  Control of Pharmaceutical and Biological Products 
(Beijing, China). Sodium dodecyl sulfate was obtained 
from Tianjin   Chemical Reagent Co Ltd (Tianjin, China). 
Pluronic® F68   (Poloxamer 188) was kindly provided by 
BASF   Corporation   (Ludwigshafen, Germany). Filters 
(0.22 µm and 0.8 µm) were supplied by Millipore Corpora-
tion (Billerica, MA). Eudragit E100 was supplied by Röhm 
Pharma as a gift (Darmstadt, Germany). Sulfatase extracted 
from Helix pomatia was a product of Sigma-Aldrich 
Chemicals Co Ltd (St Louis, MO). All other reagents were 
of chromatographic grade. Distilled water, prepared from 
deionized water, was used throughout the study.
Preparations of genistein nanoparticles
The genistein nanoparticles were prepared by a nanopre-
cipitation method.9,11,12 Genistein 5 mg and Eudragit E 
50 mg were dissolved in 2 mL of ethanol. The internal 
organic phase solutions were slowly injected into 10 mL 
of the external aqueous solution (1% Poloxamer 188 in 
water), and the mixtures were then stirred at 500 rpm for 
50 minutes. Internal organic phase solutions are always 
composed of solvents, making the drug and Eudragit 
  soluble completely, and the external aqueous phase com-
prises aqueous solution, sometimes with surfactant in it. 
The surfactant can penetrate into the genistein nanoparticles 
during the nanoprecipitation process to form a stable nano-
particle delivery system. Ethanol was completely removed 
by rotary vacuum evaporation under a water bath at 32°C. 
The nanoparticles formed were filtered using a 0.8 µm 
filter and centrifuged at 11,000 × g for 60 minutes. The 
supernatant was separated and analyzed by high-pressure 
liquid chromatography (HPLC) for free drug content. 
The genistein nanoparticles formed were isolated, washed 
three times with distilled water, and freeze-dried. Lactose 
was chosen as a cryoprotectant, which had a good freeze-
drying effect. Blank nanoparticles were prepared following 
the above method without genistein. All the nanoparticles 
were prepared in triplicate.
Particle size analysis
The mean size of the genistein nanoparticles was deter-
mined using a LB-500 dynamic light scattering particle size 
analyzer (Horiba, Kyoto, Japan). Each sample was appro-
priately diluted 100 times with distilled water for analysis. 
The particle size analyzer could measure sizes ranging from 
3 nm to 6000 nm.
Morphological analysis
A drop of the fresh nanoparticle sample was placed onto a 
carbon-coated copper grid, forming a thin liquid film. The 
films on the grid were negatively stained by addition of a 
drop of 1% (w/v) phosphotungstic acid. The excess staining 
solution was removed with filter paper, then air-dried. The 
stained films were observed on a Tecnai G2 transmission 
electron microscope (Philips, Eindhoven, The Netherlands) 
and photographed.
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Figure 1 Structure of genistein.
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Encapsulation efficiency and drug loading
The supernatant was separated by ultracentrifugation,13 and 
the encapsulation efficiency was determined by HPLC.14 The 
HPLC system consisted of a 600 pump (Waters,   Milford, MA), 
a PDA-996 ultraviolet detector (Waters), and a 717 autosam-
pler (Waters). A reversed-phase column   (DiamonsilTM C 18, 
250 mm × 4.6 mm, 5 µm, Beijing, China) was utilized for drug 
separation at 25°C. The mobile phase comprised a degassed 
mixture of methanol and water (85:15, v/v). The ﬂow rate 
of the mobile phase was maintained at 1.0 mL/minute and 
detection was performed at 261 nm. A 10 µL sample was 
injected into the HPLC column for analysis. The genistein 
concentration in the sample was determined using a calibra-
tion curve. The encapsulation efficiency and drug loading 
were determined using the following formulae:
Encapsulation efficiency (%) = encapsulated drug 
  /total drug × 100%
Drug loading (%) = mass of genistein in nanoparticles
  /mass of nanoparticles recovered 
× 100%15
The method showed excellent reproducibility, with intra-
day and interday precision of less than 2% (relative standard 
deviation), as well as excellent accuracy between 91.7% and 
100.0% for genistein. The lower limit of quantitation for 
genistein was 0.02 µg/mL.
Dissolution test
The dissolution test was performed using a drug intelligence 
dissolution tester according to the second method of the Chinese 
Pharmacopoeia dissolution procedure. Brieﬂy, lyophilized 
genistein nanoparticles in capsules and common capsules (drug 
filled in blank capsules) containing genistein approximately 
1.6 mg were put into different sinkers. Each sinker was loaded 
into 400 mL of phosphate buffer (pH 1.2) with 0.5% sodium 
dodecyl sulfate at 37° ± 0.5°C and a paddle speed of 100 rpm. 
Each sample (4 mL) was withdrawn at 5, 10, 20, 30, 45, and 
60 minutes, and an equal volume of temperature-equilibrated 
blank media was then added to the beaker. The samples were 
filtered using a 0.22 µm filter, and 10 µL was used for determi-
nation of genistein. The concentrations of drug were determined 
by HPLC analysis as already mentioned.
Animals and drug administration
The experimental protocols were approved by the animal care 
committee of Harbin Medical University,   Heilongjiang, China. 
Twelve male Sprague-Dawley rats weighing 180–220 g were 
provided by the experimental animal center at our institution. 
They were housed in an air-conditioned room with tempera-
ture maintained at 25°C ± 1°C and humidity at 55% ± 5% 
under a regular 12:12 hour light/dark cycle for one week 
prior to treatment. All animals were fed with standard rodent 
chow and water ad libitum. They were randomly divided into 
two groups, ie, one to receive genistein nanoparticles and the 
other to receive genistein suspension. The genistein suspen-
sion was prepared by suspending genistein in a 1% sodium 
carboxymethyl cellulose solution. All groups were fasted 
and given genistein suspension or genistein nanoparticles at 
a dose of 100 mg/kg by intragastric administration. Blood 
samples (approximately 0.25 mL) were collected and put 
into heparinized tubes at hours 0.17, 0.5, 1, 2, 3, 4, 6, 8 and 
12 after administration. Plasma samples were immediately 
separated by centrifugation at 3000 × g for 10 minutes and 
stored at −20°C until analysis.
Sample preparation
The 100 µL plasma samples were incubated with 100 U of 
sulfatase at 37°C for eight hours, and phenacetin 10 µg/mL in 
mobile phase and 3 mL of methyl tert-butyl ether were then 
added to the samples in 5 mL Eppendorf tubes. After vortex-
mixing for three minutes and centrifugation at 3000 × g for 
10 minutes, the supernatant was transferred to another tube 
and evaporated to dryness under a gentle stream of nitrogen 
at 40°C. The residue was reconstituted with 100 µL of mobile 
phase followed by vortex-mixing. A 20 µL aliquot of the 
supernatant was injected into the HPLC system.
HPLC assay
The concentration of genistein was determined by HPLC using 
a 600 pump (Waters, Milford MA), a PDA-996 UV   detector 
(Waters), and a 717 autosampler (Waters). A reversed-
phase column (Diamonsil TM C18, 250 mm × 4.6 mm, 5 µm, 
  Beijing, China) was utilized for drug separation at 30°C. The 
mobile phase comprised a degassed mixture of methanol and 
water (60:40, v/v). The ﬂow rate of the mobile phase was 
maintained at 1.0 mL/minute. Detection was performed at 
261 nm. The method showed excellent reproducibility, with 
an intraday and interday precision of less than 12.1% (rela-
tive standard deviation), as well as an excellent accuracy of 
between 91.2% and 106.8% for genistein. The lower limit 
of quantitation for genistein was 0.15 µg/mL. The extrac-
tion recovery of genistein and the internal standard was 
55.55% ± 6.65% and 52.88% ± 2.96%, respectively.
Genistein was stable in rat plasma samples after three 
freeze-thaw cycles, following benchtop storage at room 
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temperature for 12 hours, and in reconstituted solution after 
being kept at room temperature for 12 hours. When stored 
at −20°C, the genistein added to the plasma samples was 
found to be stable for at least 30 days.
Pharmacokinetic analysis
The chromatographic data were automatically processed to 
obtain the peak-area ratio of compound to internal standard. 
The maximum plasma concentration (Cmax) and the time to 
reach this peak concentration (Tmax) were determined by 
visual inspection of the experimental data. The elimination 
rate constant (Ke) was calculated by applying the least-
squares regression technique to the data for the last three 
or four points of the plasma concentration-time curve, and 
the half-life (t1/2) of the drug was obtained by 0.693/Ke. The 
area under the curve (AUC) was calculated by the trapezoid 
method. The relative bioavailability of genistein nanopar-
ticles (test formulation) to the genistein suspension (reference 
formulation) was calculated using the following equation:
 
Relative BA (%) 
AUC
AUC
Dose  
Dose
test
reference
reference
tes
=×
t t
The data were presented as the mean ± standard error of 
the mean for the individual groups. The unpaired Student’s 
t-test was used to determine any statistically significant 
differences. Differences were considered to be statistically 
significant at P , 0.05.
Results
Characterization of genistein 
nanoparticles
Genistein nanoparticles prepared by the nanoprecipitation 
technique showed a blue opalescent and uniform appearance. 
The optimal encapsulation efficiency and drug loading of the 
genistein nanoparticle formulation were 50.61% ± 0.41% and 
5.02% ± 0.04%, respectively. The size of the genistein nano-
particles was approximately 120.0 ± 9.25 nm when diluted 
100 times with distilled water (Figure 2). The drug-loaded 
nanoparticles were small, spherical, and uniform, and there 
was no adhesion between particles seen on transmission 
electron microscopy (Figure 3).
In vitro dissolution study
Dissolution studies were performed for lyophilized genistein 
nanoparticles filled in capsules and for conventional genistein 
capsules. The dissolution rates of the drug from these 
preparations were evaluated in pH 1.2 phosphate buffer with 
0.5% sodium dodecyl sulfate. The release percentages of the 
drug from genistein nanoparticles were significantly higher 
than those from conventional genistein capsules (Figure 4). The 
release of genistein nanoparticles was more than 80% within 
20 minutes. In contrast, less than 30% of genistein from the 
conventional genistein capsules dissolved within 20 minutes.
Bioavailability studies
The plasma profile of genistein in rats following oral admin-
istration of a single 100 mg/kg dose of genistein was inves-
tigated in the two groups. The plasma concentration profiles 
for genistein in the nanoparticles showed significantly greater 
improvement on oral absorption than did the genistein sus-
pension (Figure 5). The main pharmacokinetic parameters 
for genistein in the two formulations are summarized in 
Table 1. The results show pronounced differences in the 
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Figure 2 Size distribution of genistein nanoparticles.
Figure 3 Transmission electron micrograph of genistein nanoparticles.
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pharmacokinetics of genistein following oral administration 
in rats. The difference in Cmax value of 5.32 ± 0.71 µg/mL 
in the formulation group and 2.17 ± 0.87 µg/mL in the con-
trol group was statistically significant (P , 0.05). Marked 
differences were also observed for the AUC. The AUC0→12 
for the genistein suspension was 10.8 µg/mL⋅hour and 
that for the genistein nanoparticles was 26.1 µg/mL⋅hour 
(P , 0.05). The relative bioavailability of genistein from the 
nanoparticles compared with the suspension was 241.8%, 
suggesting that a nanoparticle formulation could improve 
the oral absorption of genistein.
Discussion
In previous studies, various methods have been used to 
prepare nanoparticles, including a water-in oil-in-water 
(w1/o/w2) double emulsion method which is only used for 
hydrophilic drugs, and a film ultrasonic dispersion process 
which is complex, time-consuming, and difficult to control. 
Due to the limitations of these methods and the conditions of 
this experiment, the nanoprecipitation technique was used, 
based on its advantages of being relatively simple and rapid 
to perform. Moreover, it has been demonstrated in the litera-
ture that this nanoparticle delivery system can substantially 
transform the original physicochemical properties of drugs 
and greatly improve their bioavailability.16,17
For this experiment, a series of solvents, ie, ethanol, 
acetone, and dichloromethane, were used to investigate 
their inﬂuence on the preparation of genistein nanoparticles. 
Of these, the ethanol solvent was able to dissolve the drug 
and the polymer well and was quite clear, while acetone was 
more toxic than ethanol, and dichloromethane could not dis-
solve the drug or polymer completely. Therefore, ethanol was 
selected as the organic solvent for further study.
There were several reasons for enhancement of the drug 
dissolution rate. First, both genistein and Eudragit E are 
hydrophobic substances, which implies that a stronger 
  affinity will be generated between them when blended with 
the organic ethanol solvent during the process of nanoparti-
cle preparation. Second, the enhancement of drug dissolution 
could be attributed to the reduction of drug particle size, the 
enhanced hydrophilic properties of the drug when encap-
sulated in Eudragit E polymer, and enhanced wettability at 
the acidic pH provided by the dissolved Eudragit E. Finally, 
the hydrophilic and hydrophobic portion of Poloxamer 
188 can penetrate into genistein nanoparticles during the 
nanoprecipitation process to form a stable nanoparticle 
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Figure 4 Dissolution profiles of genistein from genistein nanoparticles (•) and 
genistein capsules (○). Tests were conducted in 400 mL of pH 1.2 phosphate buffer 
with 0.5% sodium dodecyl sulfate at 37°C ± 0.5°C with a rotation speed of 100 rpm. 
Each value is the mean ± standard deviation (n = 3).
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Figure  5  Genistein  plasma  concentration-time  profiles  of  either  genistein 
nanoparticles (•) or genistein suspension (○) following oral administration of a 
single dose of 100 mg/kg genistein in rats. Each value is the mean ± standard error 
(n = 6).
Table  1  Main  pharmacokinetic  parameters  of  genistein  after 
a  single  100  mg/kg  oral  dose  of  genistein  in  two  groups,  ie,  a   
nanoparticle group and a suspension group
Parameters Genistein 
nanoparticles
Suspensions
Cmax (µg/mL)   5.32 ± 0.71* 2.17 ± 0.40
Tmax (h)   2.50 ± 0.34 2.83 ± 0.31
Ke (h−1) 0.166 ± 0.025 0.198 ± 0.030
t1/2 (h)   4.60 ± 0.59 4.24 ± 1.03
AUC0→12 h (µg/mL⋅h)   26.1 ± 3.94* 10.8 ± 0.87
Relative BA (%) 241.8 ± 32.79 100
Notes: Each value is the mean ± standard error, n = 6, *P , 0.05. 
Abbreviations: Cmax, peak plasma concentration; Tmax, time to peak concentration; 
t1/2, elimination half-life; AUC, area under the curve; Ke, elimination rate constant; 
Relative BA, relative bioavailability.
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delivery system. Similar observations have been reported 
elsewhere. 9,18
Nanoparticle size is an important factor in gastrointes-
tinal absorption, because only nanoparticles of appropriate 
size can be absorbed significantly. Several mechanisms 
for gastrointestinal absorption of nanoparticles have been 
reported, ie, cell bypass channel transport, intestinal epithelial 
cells cross-cell uptake, and collection of lymph nodes in the 
ileum (Peyer’s patches) of microfold cells.19,20 Studies have 
documented that when rats are given PLGA particles sized 
100 nm, 500 nm, 1 µm, and 10 µm by oral administration, 
the amount of 100 nm particles captured by Peyer’s patches 
is 10–250 times greater than that of the other particle sizes.21 
Further studies have shown a range of particle sizes to be suit-
able for gastrointestinal absorption,22 and that nanoparticles 
of around 100 nm are absorbed several times more efficiently 
than those of larger size.21 The nanoparticles prepared in the 
present experiment were 120 nm, and could be absorbed 
well by the gastrointestinal tract, and thus would play a key 
role in efficacy.
There has been some research reporting on different 
genistein doses being administered to rats. For example, 
genistein 40 mg/kg was orally administered in a pharma-
cokinetic rat model,23 and a dose of 480 mg/kg was used in 
another study to investigate toxicity.24 In the present study, 
an intermediate dose of 100 mg/kg was administered.
There has been a report of genistein being administered 
orally in healthy premenopausal women to investigate the 
pharmacokinetics of genistein. Pharmacokinetic analysis 
of the plasma concentration-time curves showed that the 
t1/2 of genistein was 7.77 hours.25 Similar findings have 
been reported by other investigators. Pharmacokinetic 
analysis showed that the serum half-life of genistein was 
4.53 ± 1.40 hours in rats.23 In the present study, the t1/2 of 
genistein was 4.60 ± 0.59 hours.
The faster absorption of genistein nanoparticles than that 
of genistein alone is mainly due to the higher hydrophilicity 
and dispersion of the nanoparticles. There were differences in 
the plasma concentration-time profiles and pharmacokinetic 
parameters of genistein in individual rats after oral admin-
istration in the two groups. This can be attributed to the fact 
that the absorption of genistein and activity of sulfatase can 
be very different from each other.
Sulfatase is from Helix pomatia, and has deglucuroni-
dation and desulfation activities. Glucoside conjugates 
and sulfate conjugates of genistein are the major naturally 
occurring isoﬂavones in soybean and soybean-based food 
products. After being absorbed, genistein exists in the 
  systemic circulation in the form of multiple molecules, such 
as glucuronide and sulfate conjugates.26 These conjugates of 
genistein are converted to the aglycone form by sulfatase. 
Genistein glucuronides become active in vivo by hydrolysis, 
and only in this way can genistein have strong physiological 
functions. Sulfatase treatment is necessary because it plays an 
important role in the measurement of genistein concentration 
in plasma samples. A similar observation has been reported 
by other investigators.23,27
In conclusion, genistein, the principal soy isoﬂavone, is 
a molecule of great interest as a lead compound in antican-
cer drug design and an innovative chemotherapeutic agent. 
However, genistein is poorly soluble in water, and the dis-
solution and bioavailability of the drug from the solid oral 
preparations are different and not reproducible. In this study, 
the use of nanoparticles improved the dissolution of genistein. 
Furthermore, nanoparticles showed better oral absorption 
than the genistein suspension based on in vivo bioavailabil-
ity studies. The relative bioavailability of genistein-loaded 
nanoparticles was 241.8% compared with the genistein 
suspension. In summary, Eudragit E nanoparticles offer a 
promising means to improve the solubility and bioavailability 
of genistein after oral administration.
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